Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis
Gavin M. Traber, Kailen Mark, Aarthi Jayanthan, Hee-Don Chae, Minyoung Youn, Jenny Youm, Nick J. Sharp, Sandra E. Dunn, Kathleen M. Sakamoto · 2026
Read Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis by Gavin M. Traber, Kailen Mark, Aarthi Jayanthan, Hee-Don Chae, Minyoung Youn, Jenny Youm, Nick J. Sharp, Sandra E. Dunn, Kathleen M. Sakamoto (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421334.txt.
Description
Gavin M. Traber and eight colleagues write to the editor in 2026 about an experimental drug, PMD-026, for acute myeloid leukaemia carrying FLT3 activation. This leukaemia grows fast, relapses often, and leaves adults with five-year survival near 30 percent, while intensive chemotherapy harms many patients who cannot tolerate it.
PMD-026 blocks RSK, a signalling protein downstream of FLT3. The letter reports that selective RSK blockade suppressed the FLT3-driven leukaemia while sparing normal blood formation, the balance that conventional chemotherapy fails to strike. The authors frame the selectivity as the point: a mechanism-based drug that hits the cancer's wiring without the broad damage of cytotoxic treatment.
Catalog record
| CREATOR | Gavin M. Traber, Kailen Mark, Aarthi Jayanthan, Hee-Don Chae, Minyoung Youn, Jenny Youm, Nick J. Sharp, Sandra E. Dunn, Kathleen M. Sakamoto |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25734 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |